Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that ...

Medically reviewed by Lindsay Cook, PharmDFact checked by Khara ScheppmannPsoriasis is usually treated with a combination of ...